Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making

Annals of Surgical Oncology

Volumn 23, Issue 10, 2016, Pages 3106-3111

  Boughey, Judy C ^a   Attai, Deanna J ^b   Chen, Steven L ^c   Cody, Hiram S ^d   Dietz, Jill R ^e   Feldman, Sheldon M ^f   Greenberg, Caprice C ^g   Kass, Rena B ^h   Landercasper, Jeffrey ⁱ   Lemaine, Valerie ^a   MacNeill, Fiona ^j   Margenthaler, Julie A ^k   Song, David H ^l   Staley, Alicia C ^m   Wilke, Lee G ^g   Willey, Shawna C ⁿ   Yao, Katharine A ^o  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OasisMD ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Columbia University ^*  (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ GUNDERSEN HEALTH SYSTEM   (United States)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k Center for Advanced Medicine   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m Akari Healthcare   (United States)

ⁿ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^o NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SURGERY; CONSENSUS; CONTRALATERAL PROPHYLACTIC MASTECTOMY; DISEASE SURVEILLANCE; EUROPE; HEALTH CARE COST; HUMAN; LYMPH NODE DISSECTION; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COUNSELING; PROPHYLACTIC MASTECTOMY; QUALITY CONTROL; SENTINEL LYMPH NODE; SHARED DECISION MAKING; SOCIAL PSYCHOLOGY; SURGEON; UNITED KINGDOM; BREAST TUMOR; COST BENEFIT ANALYSIS; COUNSELING; DECISION MAKING; ECONOMICS; FEMALE; PATHOLOGY; PATIENT PREFERENCE; PATIENT SATISFACTION; PSYCHOLOGY; SENTINEL LYMPH NODE BIOPSY; STANDARDS; TRENDS; UNITED STATES; WATCHFUL WAITING;

CONSENSUS; COST-BENEFIT ANALYSIS; COUNSELING; DECISION MAKING; EUROPE; FEMALE; HUMANS; PATIENT PREFERENCE; PATIENT SATISFACTION; PROPHYLACTIC MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; SURGEONS; UNILATERAL BREAST NEOPLASMS; UNITED STATES; WATCHFUL WAITING;

EID: 84979993782     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5408-8     Document Type: Article

References (40)

1. Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: the data on CPM outcomes and risks. Ann Surg Oncol. 2016.
2. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–15.
3. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107:1440–7.
4. Nagaraja V, Edirimanne S, Eslick GD. Is sentinel lymph node biopsy necessary in patients undergoing prophylactic mastectomy? A systematic review and meta-analysis. Breast J. 2016;22:158–65.
5. Yi M, Meric-Bernstam F, Middleton LP, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009;115:962–71.
6. Murthy V, Chamberlain RS. Prophylactic mastectomy in patients at high risk: is there a role for sentinel lymph node biopsy? Clin Breast Cancer. 2013;13:180–7.
7. Boughey JC, Cormier JN, Xing Y, et al. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007;110:2542–50.
8. Nasser SM, Smith SG, Chagpar AB. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. J Surg Res. 2010;164:188–92.
9. Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, Cox CE. Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. J Am Coll Surg. 2009;209:746–52.
10. Czyszczon IA, Roland L, Sahoo S. Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy. J Surg Oncol. 2012;105:650–4.
11. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295–303.
12. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006;144:397–406.
13. Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125:837–47.
14. Cott Chubiz JE, Lee JM, Gilmore ME, et al. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer. 2013;119:1266–76.
15. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427–37.
16. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.
17. Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29:2993–3000.
18. Roberts A, Habibi M, Frick KD. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. Ann Surg Oncol. 2014;21:2209–17.
19. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23:7849–56.
20. Rosenberg SM, Sepucha K, Ruddy KJ, et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol. 2015;22:3809–15.
21. Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350–6.
22. Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol. 2011;18:3110–6.
23. Altschuler A, Nekhlyudov L, Rolnick SJ, et al. Positive, negative, and disparate–women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J. 2008;14:25–32.
24. Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, Borgen PI. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546–52.
25. Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer. 2012;48:3150–6.
26. Neuburger J, MacNeill F, Jeevan R, van der Meulen JH, Cromwell DA. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open. 2013;3:e003179.
27. Guth U, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy—a trend made in USA? Eur J Surg Oncol. 2012;38:296–301.
28. Basu NN, Littlechild S, Evans DG, Ross G, Barr L. Contralateral risk reducing mastectomy—a national survey of surgeons’ practices and perceptions. Eur J Surg Oncol. 2013;39:S64.
29. Leff DR, Ho C, Thomas H, et al. A multi-disciplinary team approach minimises prophylactic mastectomy rates. Eur J Surg Oncol. 2015;41:1005–12.
30. Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC. ‘Taking control of cancer’: understanding women’s choice for mastectomy. Ann Surg Oncol. 2015;22:383–91.
31. Rosenberg SM, Partridge AH. Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg. 2014;149:589–90.
32. Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med. 2014;16:516–21.
33. Soran A, Ibrahim A, Kanbour M, et al. Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer. Am J Clin Oncol. 2015;38:179–183.
34. Hawley ST, Jagsi R, Morrow M, Janz NK, Hamilton A, Graff JJ, Katz SJ. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014;149:582–9.
35. Pantalon MV Sledge WH, Bauer SF, et al. Important medical decisions: Using brief motivational interviewing to enhance patients’ autonomous decision-making. J Psychiatr Pract. 2013;19:98–108.
36. Akechi T, Momino K, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Iwata H. Contribution of problem-solving skills to fear of recurrence in breast cancer survivors. Breast Cancer Res Treat. 2014;145:205–10.
37. Nekhlyudov L, Bower M, Herrinton LJ, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst. 2005;35:55–60.
38. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013;159:373–81.
39. Parker PA, Peterson SK, Bedrosian I, et al. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg. 2016;263:178–83.
40. Sepucha KR, Fowler FJ, Jr., Mulley AG, Jr. Policy support for patient-centered care: the need for measurable improvements in decision quality. Health Aff (Millwood). 2004;Suppl Variation:VAR54–62.